Dale M Needham1, Elizabeth Colantuoni2, Victor D Dinglas3, Catherine L Hough4, Amy W Wozniak2, James C Jackson5, Peter E Morris6, Pedro A Mendez-Tellez7, E Wesley Ely8, Ramona O Hopkins9. 1. Outcomes After Critical Illness and Surgery Group, Johns Hopkins University, Baltimore, MD, USA; Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: dale.needham@jhmi.edu. 2. Outcomes After Critical Illness and Surgery Group, Johns Hopkins University, Baltimore, MD, USA; Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. 3. Outcomes After Critical Illness and Surgery Group, Johns Hopkins University, Baltimore, MD, USA; Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Division of Pulmonary and Critical Care Medicine, Harborview Medical Center, University of Washington, Seattle, WA, USA. 5. Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA. 6. Division of Pulmonary, Critical Care & Sleep Medicine, University of Kentucky, Lexington, KY, USA. 7. Outcomes After Critical Illness and Surgery Group, Johns Hopkins University, Baltimore, MD, USA; Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 8. Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA; Geriatric Research, Education and Clinical Center Service, Department of Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN, USA. 9. Department of Medicine, Pulmonary and Critical Care Division, Intermountain Medical Center, Murray, UT, USA; Psychology Department and Neuroscience Center, Brigham Young University, Provo, UT, USA; Center for Humanizing Critical Care, Intermountain Health Care, Murray, UT, USA.
Abstract
BACKGROUND:Delirium is common in mechanically ventilated patients and is associated with cognitive impairment lasting at least 1 year after hospital discharge. Preclinical and observational studies suggest that the use of statins might reduce delirium in intensive care. We assessed whether the pleiotropic effects of statins can reduce delirium in intensive care and decrease subsequent cognitive impairment in a randomised controlled trial. METHODS: We did this ancillary study within the SAILS trial, a randomised controlled trial assessing mortality and ventilator-free days for rosuvastatin versus placebo for patients with sepsis-associated acute respiratory distress syndrome. This study was done at 35 hospitals in the USA. Patients were randomly assigned in permuted blocks of eight and stratified by hospital to receive either rosuvastatin (40 mg loading dose and then 20 mg daily until the earliest of 3 days after discharge from intensive care, study day 28, or death) or placebo. Patients and investigators were masked to treatment assignment. Delirium was assessed with the validated Confusion Assessment Method for intensive care. Cognitive function was assessed with tests for executive function, language, verbal reasoning and concept formation, and working, immediate, and delayed memory. We defined cognitive impairment as having one of these domains at least two SDs below population norms or at least two domains at least 1·5 SDs below norms. The primary endpoint was daily delirium status in intensive care up to 28 days in the intention-to-treat population and secondary endpoints were cognitive function at 6 months and 12 months. This trial is registered with ClinicalTrials.gov (NCT00979121 and NCT00719446). FINDINGS:272 patients were assessed for delirium daily in intensive care. The mean proportion of days with delirium was 34% (SD 30%) in the rosuvastatin group versus 31% (29%) in the placebo group; hazard ratio 1·14, 95% CI 0·92-1·41, p=0·22. At 6 months, 19 (36%) of 53 patients in the rosuvastatin group versus 29 (38%) of 77 in the placebo group had cognitive impairment, with no significant difference between groups (treatment effect 0·93, 95% CI 0·39-2·22; p=0·87). At 12 months, 20 (30%) of 67 patients versus 23 (28%) of 81 patients had cognitive impairment, with no significant difference between groups (treatment effect 1·1, 95% CI 0·5-2·6; p=0·82). INTERPRETATION: Most patients had delirium, with around a third of survivors having cognitive impairment over 1 year of follow-up. Despite encouraging preclinical and observational studies, this trial shows no benefit of rosuvastatin in reducing delirium in intensive care or cognitive impairment during 12 months of follow-up although the study was not powered for superiority. Thus, there is continued need to evaluate interventions aimed at attenuating intensive care and post-intensive-care cognitive impairments commonly observed in this population. FUNDING: National Heart, Lung and Blood Institute; Johns Hopkins Institute for Clinical and Translational Research; the SAILS trial was also supported by AstraZeneca.
RCT Entities:
BACKGROUND:Delirium is common in mechanically ventilated patients and is associated with cognitive impairment lasting at least 1 year after hospital discharge. Preclinical and observational studies suggest that the use of statins might reduce delirium in intensive care. We assessed whether the pleiotropic effects of statins can reduce delirium in intensive care and decrease subsequent cognitive impairment in a randomised controlled trial. METHODS: We did this ancillary study within the SAILS trial, a randomised controlled trial assessing mortality and ventilator-free days for rosuvastatin versus placebo for patients with sepsis-associated acute respiratory distress syndrome. This study was done at 35 hospitals in the USA. Patients were randomly assigned in permuted blocks of eight and stratified by hospital to receive either rosuvastatin (40 mg loading dose and then 20 mg daily until the earliest of 3 days after discharge from intensive care, study day 28, or death) or placebo. Patients and investigators were masked to treatment assignment. Delirium was assessed with the validated Confusion Assessment Method for intensive care. Cognitive function was assessed with tests for executive function, language, verbal reasoning and concept formation, and working, immediate, and delayed memory. We defined cognitive impairment as having one of these domains at least two SDs below population norms or at least two domains at least 1·5 SDs below norms. The primary endpoint was daily delirium status in intensive care up to 28 days in the intention-to-treat population and secondary endpoints were cognitive function at 6 months and 12 months. This trial is registered with ClinicalTrials.gov (NCT00979121 and NCT00719446). FINDINGS: 272 patients were assessed for delirium daily in intensive care. The mean proportion of days with delirium was 34% (SD 30%) in the rosuvastatin group versus 31% (29%) in the placebo group; hazard ratio 1·14, 95% CI 0·92-1·41, p=0·22. At 6 months, 19 (36%) of 53 patients in the rosuvastatin group versus 29 (38%) of 77 in the placebo group had cognitive impairment, with no significant difference between groups (treatment effect 0·93, 95% CI 0·39-2·22; p=0·87). At 12 months, 20 (30%) of 67 patients versus 23 (28%) of 81 patients had cognitive impairment, with no significant difference between groups (treatment effect 1·1, 95% CI 0·5-2·6; p=0·82). INTERPRETATION: Most patients had delirium, with around a third of survivors having cognitive impairment over 1 year of follow-up. Despite encouraging preclinical and observational studies, this trial shows no benefit of rosuvastatin in reducing delirium in intensive care or cognitive impairment during 12 months of follow-up although the study was not powered for superiority. Thus, there is continued need to evaluate interventions aimed at attenuating intensive care and post-intensive-care cognitive impairments commonly observed in this population. FUNDING: National Heart, Lung and Blood Institute; Johns Hopkins Institute for Clinical and Translational Research; the SAILS trial was also supported by AstraZeneca.
Authors: Herbert P Wiedemann; Arthur P Wheeler; Gordon R Bernard; B Taylor Thompson; Douglas Hayden; Ben deBoisblanc; Alfred F Connors; R Duncan Hite; Andrea L Harabin Journal: N Engl J Med Date: 2006-05-21 Impact factor: 91.245
Authors: Rita Katznelson; George N Djaiani; Michael A Borger; Zeev Friedman; Susan E Abbey; Ludwik Fedorko; Jacek Karski; Nicholas Mitsakakis; Jo Carroll; W Scott Beattie Journal: Anesthesiology Date: 2009-01 Impact factor: 7.892
Authors: Jason D Christie; Rosette C Plotkin Biester; Darren B Taichman; William H Shull; John Hansen-Flaschen; Judy A Shea; Ramona O Hopkins Journal: J Crit Care Date: 2006-06 Impact factor: 3.425
Authors: Pim van der Harst; Folkert W Asselbergs; Hans L Hillege; Stephan J L Bakker; Adriaan A Voors; Dirk J van Veldhuisen; Wiek H van Gilst Journal: Am J Cardiol Date: 2007-11-15 Impact factor: 2.778
Authors: Marius Terblanche; Yaniv Almog; Robert S Rosenson; Terry S Smith; Daniel G Hackam Journal: Lancet Infect Dis Date: 2007-05 Impact factor: 25.071
Authors: Haichen Wang; John R Lynch; Pingping Song; Hyuk-Jun Yang; Robert B Yates; Brian Mace; David S Warner; John R Guyton; Daniel T Laskowitz Journal: Exp Neurol Date: 2007-04-27 Impact factor: 5.330
Authors: Karen A Robinson; Cheryl R Dennison; Dawn M Wayman; Peter J Pronovost; Dale M Needham Journal: J Clin Epidemiol Date: 2007-05-10 Impact factor: 6.437
Authors: Samuel M Brown; Emily L Wilson; Angela P Presson; Victor D Dinglas; Tom Greene; Ramona O Hopkins; Dale M Needham Journal: Thorax Date: 2017-08-04 Impact factor: 9.139
Authors: Joel Kohler; Friedrich Borchers; Matthias Endres; Björn Weiss; Claudia Spies; Julius Valentin Emmrich Journal: Dtsch Arztebl Int Date: 2019-09-20 Impact factor: 5.594
Authors: Pratik P Pandharipande; E Wesley Ely; Rakesh C Arora; Michele C Balas; Malaz A Boustani; Gabriel Heras La Calle; Colm Cunningham; John W Devlin; Julius Elefante; Jin H Han; Alasdair M MacLullich; José R Maldonado; Alessandro Morandi; Dale M Needham; Valerie J Page; Louise Rose; Jorge I F Salluh; Tarek Sharshar; Yahya Shehabi; Yoanna Skrobik; Arjen J C Slooter; Heidi A B Smith Journal: Intensive Care Med Date: 2017-06-13 Impact factor: 17.440
Authors: Victor D Dinglas; Elizabeth Colantuoni; E Wesley Ely; Catherine L Hough; Peter E Morris; Pedro A Mendez-Tellez; Amy W Wozniak; Ramona O Hopkins; Dale M Needham Journal: J Thorac Dis Date: 2016-11 Impact factor: 2.895
Authors: Carla M Sevin; Sarah L Bloom; James C Jackson; Li Wang; E Wesley Ely; Joanna L Stollings Journal: J Crit Care Date: 2018-08 Impact factor: 3.425
Authors: Victor D Dinglas; Caroline M Chessare; Wesley E Davis; Ann Parker; Lisa Aronson Friedman; Elizabeth Colantuoni; Clifton O Bingham; Alison E Turnbull; Dale M Needham Journal: Thorax Date: 2017-07-29 Impact factor: 9.139
Authors: Marcos G Lopez; Christopher G Hughes; Anthony DeMatteo; Jason B O'Neal; J Brennan McNeil; Matthew S Shotwell; Jennifer Morse; Michael R Petracek; Ashish S Shah; Nancy J Brown; Frederic T Billings Journal: Anesthesiology Date: 2020-03 Impact factor: 7.892
Authors: Christopher G Hughes; Christina S Boncyk; Deborah J Culley; Lee A Fleisher; Jacqueline M Leung; David L McDonagh; Tong J Gan; Matthew D McEvoy; Timothy E Miller Journal: Anesth Analg Date: 2020-06 Impact factor: 5.108